Impact of praliciguat, a soluble guanylate cyclase stimulator, on blood pressure and metabolic parameters in patients with diabetes and hypertension

Publication Authors:

Seferovic, J.P.; Wilson, P; Carlson, K.E.; Jung, J; Wakefield, J.D.; Miller, P; Chickering, J.G.; Morrow, L; Currie, M.G.; Milne, G.T.; Profy, A.T.; Hanrahan, J.P.

Poster presented at 54th European Association for the Study of Diabetes (EASD) Annual Meeting, Berlin, Germany, October, 2018.

About

About this Poster:

Praliciguat (IW-1973), a soluble guanylate cyclase stimulator, increased nitric oxide (NO)-mediated signaling and reduced fasting plasma glucose and proteinuria in an animal model of diabetic nephropathy. In healthy subjects, repeated oral doses of praliciguat (15-40 mg) were well tolerated and lowered blood pressure (BP). We evaluated 2 dosing regimens of praliciguat in a phase 2a trial in patients with type 2 diabetes mellitus (T2DM) and hypertension (HTN).

VIEW
Impact of praliciguat, a soluble guanylate cyclase stimulator, on blood pressure and metabolic parameters in patients with diabetes and hypertension thumbnail